Best HIPAA Compliance Software for HRT and TRT Clinics (2026)

Best HIPAA Compliance Software for HRT and TRT Clinics (2026)

HRT (hormone replacement therapy) and TRT (testosterone replacement therapy) clinics emerged alongside GLP-1 weight management as a parallel category of independent telehealth-first specialty practice. The compliance profile is related but distinct: HRT/TRT adds DEA Schedule III controlled-substance handling, prescription drug monitoring program (PDMP) reporting, and significantly higher state board scrutiny of telemedicine prescribing.

This guide covers what to look for in compliance software for an HRT/TRT clinic and the seven features that distinguish HRT/TRT-fit tools. (See our broader comparison of HIPAA compliance platforms for the market map.)

The HRT/TRT Exposure Profile

Seven characteristics make HRT/TRT clinics distinct:

DEA Schedule III controlled-substance handling. Testosterone is Schedule III. Prescribing requires DEA registration, secure electronic prescribing systems (EPCS), specific record retention (2-year DEA minimum, 6-year HIPAA minimum, sometimes longer state minimums), and compliance with DEA documentation rules.

Prescription Drug Monitoring Program reporting. State PDMPs require pharmacies (and increasingly providers) to report controlled-substance dispensing. PDMP queries before prescribing are required in most states. The integration with PDMP systems is HIPAA-relevant.

Compounding pharmacy supply chain. Like GLP-1 clinics, HRT/TRT clinics commonly use 503A compounding pharmacies. The pharmacy is a business associate; the supply chain has additional DEA layering because Schedule III drugs move through it.

Telehealth-first patient acquisition. Most HRT/TRT clinics operate predominantly via telehealth. State board scrutiny of telemedicine prescribing of controlled substances is particularly heavy. The DEA/HHS fourth temporary extension (effective Jan 1, 2026 through Dec 31, 2026) currently permits DEA-registered practitioners to prescribe Schedule II–V controlled substances via audio-video telemedicine without a prior in-person evaluation — but the underlying Ryan Haight Act in-person requirement is expected to be reinstated under a forthcoming DEA final rule. Practices need a workflow that survives both states of regulation.

Lab workflow. Hormone panels, lipid panels, hematocrit monitoring, PSA monitoring — extensive lab work is part of routine HRT/TRT care. Lab partners are business associates; lab order and results workflows are HIPAA-relevant.

State board scrutiny. State medical boards have actively investigated HRT/TRT clinic prescribing practices in recent years. Some states have specific licensure or registration requirements beyond standard medical licensure.

Membership-based long-term care. HRT and TRT are long-term therapies. Patients engage on multi-month or multi-year membership models with cumulative PHI per patient.

These seven produce a compliance overlay that exceeds what HIPAA software alone addresses.

What to Look For in HRT/TRT Compliance Software

1. DEA Schedule III tracking

The platform should track DEA registration status, EPCS (Electronic Prescriptions for Controlled Substances) deployment, and the documentation requirements specific to Schedule III prescribing. DEA registration changes, renewals, and any enforcement actions should be surfaced to the compliance officer.

2. PDMP integration documentation

The platform should track PDMP query workflow — when queries are required (most states require pre-prescribing), the documentation of each query, and the practice's PDMP-reporting obligations if any apply.

3. Compounding pharmacy BAA tracking (with DEA layering)

Beyond standard pharmacy BAA tracking, the platform should support DEA-specific elements of the supply-chain documentation: the pharmacy's DEA registration verification, the lot tracking for Schedule III compounds, and the recall workflow.

4. Telehealth + Ryan Haight Act / DEA telemedicine compliance

Telemedicine prescribing of controlled substances is governed by the Ryan Haight Act and current DEA temporary-extension rules (most recently the fourth extension running through Dec 31, 2026). The platform should track current rule status, in-person evaluation requirements where applicable, state-specific exceptions, and DEA telemedicine registration if relevant. Because the rule is on temporary extension and a final rule is pending, the platform should also surface regulatory changes as they occur.

5. Lab order workflow with BAA chain

Same as GLP-1 — lab partner BAAs, lab order disclosure logging, results return workflow.

6. State-specific telemedicine prescribing overlay

The platform should be aware of state-by-state telemedicine prescribing rules for Schedule III drugs. Some states allow it broadly; some restrict it significantly; some require in-person evaluation. The compliance overlay should be applied automatically.

7. Membership lifecycle with controlled-substance handoff

When a patient cancels HRT/TRT membership, the platform must handle the controlled-substance handoff appropriately — outstanding prescriptions, refills, transfer to another provider, or discontinuation. The documentation around this is DEA-relevant, not just HIPAA-relevant.

Price Bands That Make Sense for HRT/TRT Clinics

$39 to $99 per month — entry tier. Functional for solo-provider HRT/TRT clinics with very limited patient volume. Almost always too thin for the regulatory overlay HRT/TRT actually requires.

$99 to $300 per month — recommended tier for most HRT/TRT clinics. Adds DEA tracking, PDMP integration, compounding pharmacy BAA with DEA layering, Ryan Haight Act compliance, lab workflow, state-specific overlay, and membership lifecycle. Right for typical 1-5 provider HRT/TRT clinic with 200-2,000 active patients.

$300 to $800 per month — multi-state tier. For HRT/TRT operations across multiple states with significant state-overlay complexity.

Above $800 per month — overbuying for standalone HRT/TRT clinic.

What to Avoid

Platforms without controlled-substance compliance. Schedule III handling is not optional. Any platform that doesn't address DEA and PDMP is missing the core compliance workflow.

Generic medical platforms. HRT/TRT clinics have specific compliance needs that general medical practice software does not address.

Per-prescription pricing. HRT/TRT patients receive monthly prescriptions on long-term schedules. Per-prescription pricing creates significant cost.

How Patient Protect Approaches HRT/TRT Clinics

Patient Protect's Pro tier ($99/month flat per practice) includes DEA Schedule III tracking, PDMP integration documentation, compounding pharmacy BAA with DEA layering, Ryan Haight Act compliance, lab workflow, state-specific telemedicine overlay, and membership lifecycle workflow with controlled-substance handoff. Flat per-practice pricing fits the membership-revenue model.

For multi-state HRT/TRT operations, the platform supports the state-overlay layer for the specific complexity of Schedule III telemedicine prescribing.

The right compliance tool for an HRT/TRT clinic is one whose model includes DEA and PDMP as first-class concerns alongside HIPAA. Generic platforms treat HIPAA as the only regulatory layer, which leaves the most consequential compliance work unaddressed.